

DAFTAR PUSTAKA

- Abancens, M., Bustos, V., Harvey, H., McBryan, J., & Harvey, B. J. 2020. Sexual Dimorphism in Colon Cancer. *Frontiers in Oncology*. <https://doi.org/10.3389/fonc.2020.607909>
- Abraham L. Kierszenbaum, Laura L. 2016. *Histology and cell biology* Fourth edition. Library of Congress Cataloging-in-Publication Data Kierszenbaum
- Adam R. Markowsk. 2022. Simultaneous analysis of tumor-infiltrating immune cells density, tumor budding status, and presence of lymphoid follicles in CRC tissue. <https://doi.org/10.1038/s41598-022-26225-8>
- Ahmed, M. (2020). Colon Cancer: A Clinician's Perspective in 2019. *Gastroenterology Research*, 13(1), 1–10. <https://doi.org/10.14740/gr1239>
- A Lugli. 2012. Tumour budding: a promising parameter in colorectal cancer *British Journal of Cancer*. doi:10.1038/bjc.2012.127
- Alessandro Lugli. 2017. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC). Institute of Pathology, University of Bern, Murtenstrasse 31, Bern 3008, Switzerland.
- American Cancer Society (ACS). 2020. Colorectal Cancer Causes, Risk Factors, and Prevention. American Cancer Society, 5.
- American Cancer Society (ACS). 2020. Colorectal Cancer Causes, Risk Factors, and Prevention. Colorectal Cancer Facts and Figures 2020-2022. <https://www.cancer.org/content/dam/cancer-org/research/cancerfacts-and-statistics/colorectal-cancer-facts-and-figures>
- American Cancer Society. (2020). About Colorectal Cancer What Is Colorectal Cancer ? American Cancer Society, 1–15.
- Anne Trinh. 2018. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations. *British Journal of Cancer* <https://doi.org/10.1038/s41416-018-0230-7>
- Bojana Mitrovic. 2012. Tumor budding in colorectal carcinoma: time to take notice. doi:10.1038/modpathol.2012.94.
- Corgnac S, Boutet M, Kfoury M, Naltet C and Mami-chouaib F. 2018. The emerging role of CD8+ resident memory T (TRM) cells in antitumor immunity: a unique functional contribution of the CD103 integrin.. *Front. Immunol.* 9:1904. doi:10.3389/fimmu.2018.01904
- Corinna Lang-Schwarz MD. 2018. Budding and tumor—infiltrating lymphocytes — combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroup. <https://doi.org/10.1016/j.humpath.2018.05.010>
- Damjanov, I., & Fan, F. (2013). *Tumors of the Digestive System*. In *Cancer Grading Manual* (Second). Springer
- Eun-Hye Seo. (2023) CD103+ Cells and Chemokine Receptor Expression in Breast Cancer
- González-Martínez, S.; Pérez-Mies, B.; Pizarro, D.; Caniego-Casas, T.; Cortés, J.; Palacios, J. 2021. Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. *Int. J. Mol. Sci.* 2021, 22, 7398. <https://doi.org/10.3390/ijms22147398>
- Inti Zlobec and Alessandro Lugli . 2010. Epithelial mesenchymal transition and tumor budding in colorectal cancer: Tumor budding as oncotarget [g/10.18632/oncotarget.199](https://doi.org/10.18632/oncotarget.199)
- M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, et al. 2018. A new method of tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin (E)-stained tumor sections. <https://doi.org/10.1371/journal.pone.0192744>



- Ivar de Mingo Pulido.2017.TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. <https://doi.org/10.1016/j.ccell.2017.11.019>
- Johanna C. Hoffmann and Michael P. 2021.Review Integrin αE (CD103) $\beta 7$ in Epithelial Cancer. <https://doi.org/10.3390/cancers13246211>
- John R. Webb et al.2015.PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. British Columbia Cancer Agency
- John R.2014.Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer. Prognostic Significance of CD103 β TILs in Ovarian CarcinomaWebb. doi: 10.1158/1078-0432.CCR-13-1877
- Koen Brummel et al.2023.Tumour-infiltrating lymphocytes: from prognosis to treatment selection. British Journal of Cancer. <https://doi.org/10.1038/s41416-022-02119-4>
- Kumar, Vinay., Abbas, Abul K., Aster, J. C. (2021). Neoplasia. In Robbins & Cotran Pathologic Basis of Disease (Tenth Edit, pp. 267–336). Elsevier.
- Kumar, V., Abbas, A. K., & Aster, J. C. (2018). Small and Large Intestines. In ROBBINS BASIC PATHOLOGY (Tenth). Elsevier.
- Lamps, L. W., Bellizzi, A. M., Frankel, W. L., Owens, S. R., & Yantiss, R. K. (2016). Neoplasm of The Colon. In Neoplastic Gastrointestinal Patholog An Illustrated Guide. demosMEDICAL.
- Laurence.zitvogel.2014. CD103+ Dendritic Cells Producing Interleukin-12 in Anticancer Immunosurveillance Laurence Zitvogel.<http://dx.doi.org/10.1016/j.ccell.2014.10.008>
- Li Weia et al.2020.A classification based on tumor budding and immune score for patients with hepatocellular carcinoma
- Leonardo S. Lino-Silva.2018. Tumour budding in rectal cancer. A comprehensive review. Contemp Oncol.DOI: <https://doi.org/10.5114/wo.2018.77043>
- Łukasz Zadka.2021.Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer. Cancer Immunology, Immunotherapy (2021) 70:2681–2700
- Maffei V, Nicolè L and Cappellesso R.2019. RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer. Front. Oncol. 9:1255. doi: 10.3389/fonc.2019.01255
- Mami-Chouaib et al.2018. Journal for ImmunoTherapy of Cancer. 6:87 <https://doi.org/10.1186/s40425-018-0399-6>
- Natsuki et al.(2023).Significance of CD103+ tissue-resident memory T cells for predicting the effectiveness of immune checkpoint inhibitors in esophageal cancer. BMC Cancer
- Ola Marzouk and John Schofield.2011.Review of Histopathological and Molecular Prognostic Features in Colorectal Cancer.Department of Cellular Pathology, Maidstone Hospital, Hermitage Lane, Maidstone.
- 1.The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology 26: 15 doi:10.1093/annonc/mdu450.
- owitz.2019.Molecular Origins of Cancer Molecular Basis of Colorectal Cancer, Maryland Journal of Medicine.



- Spranger et al. 2017. Cancer Cell ^a 2017 Elsevier.<http://dx.doi.org/10.1016/j.ccell.2017.04.003>
- Soo-Jin Cho.2018.Tumor Budding in Colorectal Carcinoma Translating a Morphologic Score Into Clinically Meaningful Results.doi: 10.5858/ arpa.2018-0082-RA
- Sri G Thrumurthy.2016.Colorectal adenocarcinoma: risks, prevention and diagnosis honorary research fellow. BMJ 2016;353:i3590 doi: 10.1136/bmj.i3590
- Talia L. Fuchs, MD. Am J.2020. Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma A Study of 1034 Patients Volume 44.
- Thomas Duhen.2018.Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.| DOI: 10.1038/s41467-018-05072-0 | www.nature.com/naturecommunications
- Valeria Maffeis.2019.RAS,Cellular Plasticity and Tumor Budding in Colorectal Cancer. Volume 9 – 2019.<https://doi.org/10.3389/fonc.2019.01255>
- Van den Bulk J, van der Ploeg M, Ijsselsteijn ME, et al.2023. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden. Journal for ImmunoTherapy of Cancer 2023;11:e005887. doi:10.1136/ jitc-2022-005887.
- Van den Bulk et al. 2019.Genome Medicine. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype <https://doi.org/10.1186/s13073-019-0697-8>.
- Yin and Yang.2017. in Epithelial Immunology: The Roles of the α E(CD103) β 7 Integrin in T Cells.doi:10.1016/ j.jid.2017.05.02
- Zhijuan Qiu et al.2021.TGF- β : Many Paths to CD103+ CD8 T Cell Residency. 10, 989. <https://doi.org/10.3390/cells10050989>

